Galapagos NV (GLPGF)
USD 26.26
(0.0%)
USD 26.26
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.56 Billion EUR | -29.28% |
| 2022 | 2.2 Billion EUR | -13.39% |
| 2021 | 2.54 Billion EUR | -16.33% |
| 2020 | 3.04 Billion EUR | -4.56% |
| 2019 | 3.19 Billion EUR | 1317.53% |
| 2018 | 225.24 Million EUR | -17.88% |
| 2017 | 274.29 Million EUR | -15.51% |
| 2016 | 324.63 Million EUR | 318.81% |
| 2015 | 77.51 Million EUR | 20.49% |
| 2014 | 64.33 Million EUR | -46.5% |
| 2013 | 120.23 Million EUR | 2.87% |
| 2012 | 116.88 Million EUR | 173.86% |
| 2011 | 42.67 Million EUR | -6.11% |
| 2010 | 45.45 Million EUR | 30.49% |
| 2009 | 34.83 Million EUR | 0.96% |
| 2008 | 34.5 Million EUR | -31.13% |
| 2007 | 50.09 Million EUR | -13.78% |
| 2006 | 58.1 Million EUR | 184.45% |
| 2005 | 20.42 Million EUR | 289.38% |
| 2004 | 5.24 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.46 Billion EUR | -6.11% |
| 2024 Q2 | 1.38 Billion EUR | -5.89% |
| 2023 Q2 | 1.93 Billion EUR | -6.25% |
| 2023 Q4 | 1.56 Billion EUR | -14.64% |
| 2023 Q1 | 2.06 Billion EUR | -6.37% |
| 2023 Q3 | 1.82 Billion EUR | -5.6% |
| 2023 FY | 1.56 Billion EUR | -29.28% |
| 2022 Q4 | 2.2 Billion EUR | -3.22% |
| 2022 FY | 2.2 Billion EUR | -13.39% |
| 2022 Q1 | 2.45 Billion EUR | -3.77% |
| 2022 Q2 | 2.39 Billion EUR | -2.47% |
| 2022 Q3 | 2.28 Billion EUR | -4.66% |
| 2021 Q3 | 2.71 Billion EUR | -1.9% |
| 2021 FY | 2.54 Billion EUR | -16.33% |
| 2021 Q4 | 2.54 Billion EUR | -6.07% |
| 2021 Q2 | 2.76 Billion EUR | -5.03% |
| 2021 Q1 | 2.91 Billion EUR | -4.39% |
| 2020 FY | 3.04 Billion EUR | -4.56% |
| 2020 Q1 | 3.15 Billion EUR | -1.27% |
| 2020 Q2 | 3.07 Billion EUR | -2.35% |
| 2020 Q3 | 3 Billion EUR | -2.25% |
| 2020 Q4 | 3.04 Billion EUR | 1.28% |
| 2019 Q2 | 214.48 Million EUR | -4.44% |
| 2019 Q3 | 3.31 Billion EUR | 1446.28% |
| 2019 Q4 | 3.19 Billion EUR | -3.72% |
| 2019 FY | 3.19 Billion EUR | 1317.53% |
| 2019 Q1 | 224.44 Million EUR | -0.36% |
| 2018 Q2 | 318.68 Million EUR | -3.58% |
| 2018 Q3 | 297.32 Million EUR | -6.7% |
| 2018 Q1 | 330.51 Million EUR | 20.5% |
| 2018 FY | 225.24 Million EUR | -17.88% |
| 2018 Q4 | 225.24 Million EUR | -24.24% |
| 2017 Q3 | 154.53 Million EUR | -48.37% |
| 2017 Q4 | 274.29 Million EUR | 77.5% |
| 2017 FY | 274.29 Million EUR | -15.51% |
| 2017 Q1 | 324.66 Million EUR | 0.01% |
| 2017 Q2 | 299.32 Million EUR | -7.8% |
| 2016 Q3 | 334.27 Million EUR | -0.73% |
| 2016 FY | 324.63 Million EUR | 318.81% |
| 2016 Q4 | 324.63 Million EUR | -2.88% |
| 2016 Q2 | 336.72 Million EUR | -4.0% |
| 2016 Q1 | 350.74 Million EUR | 352.48% |
| 2015 Q4 | 77.51 Million EUR | 83.43% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 FY | 77.51 Million EUR | 20.49% |
| 2015 Q2 | 44.8 Million EUR | 0.0% |
| 2015 Q3 | 42.25 Million EUR | -5.69% |
| 2014 Q4 | 64.33 Million EUR | 0.0% |
| 2014 FY | 64.33 Million EUR | -46.5% |
| 2014 Q1 | 79.99 Million EUR | -33.47% |
| 2014 Q2 | 79.96 Million EUR | -0.03% |
| 2013 Q3 | 120.23 Million EUR | 11.11% |
| 2013 FY | 120.23 Million EUR | 2.87% |
| 2013 Q2 | 108.21 Million EUR | 0.0% |
| 2013 Q1 | 108.21 Million EUR | -7.41% |
| 2013 Q4 | 120.23 Million EUR | 0.0% |
| 2012 Q4 | 116.88 Million EUR | 0.0% |
| 2012 FY | 116.88 Million EUR | 173.86% |
| 2012 Q2 | 130.99 Million EUR | 0.0% |
| 2011 Q4 | 42.67 Million EUR | 0.0% |
| 2011 Q2 | 34.69 Million EUR | 0.0% |
| 2011 FY | 42.67 Million EUR | -6.11% |
| 2010 Q4 | 45.45 Million EUR | 0.0% |
| 2010 Q2 | 36.55 Million EUR | 0.0% |
| 2010 FY | 45.45 Million EUR | 30.49% |
| 2009 Q2 | 26.97 Million EUR | 0.0% |
| 2009 FY | 34.83 Million EUR | 0.96% |
| 2009 Q4 | 34.83 Million EUR | 0.0% |
| 2008 Q4 | 34.5 Million EUR | 0.0% |
| 2008 FY | 34.5 Million EUR | -31.13% |
| 2007 FY | 50.09 Million EUR | -13.78% |
| 2006 FY | 58.1 Million EUR | 184.45% |
| 2005 FY | 20.42 Million EUR | 289.38% |
| 2004 FY | 5.24 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -2829.988% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -16199.587% |
| SQZ Biotechnologies Company | 50.03 Million USD | -3021.225% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -2055.11% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -2546.539% |
| Mesoblast Limited | 188.44 Million USD | -728.8% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -40452.014% |
| Genus plc | 485 Million USD | -222.027% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -26631.667% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -61967.823% |
| Marizyme, Inc. | 26.67 Million USD | -5754.877% |
| ContraFect Corporation | 32.53 Million USD | -4701.051% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -41000.789% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -78728.229% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -40703.909% |
| Intellipharmaceutics International Inc. | 12 Million USD | -12905.748% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -13160.351% |
| MultiCell Technologies, Inc. | 1617.67 USD | -96548021.681% |
| Accustem Sciences Inc. | 1.07 Million USD | -144615.86% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -1917.425% |
| EV Biologics, Inc. | 2.11 Million USD | -73742.981% |
| Q BioMed Inc. | 8.13 Million USD | -19103.759% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -1783.198% |
| Neon Bloom, Inc. | 1.22 Million USD | -127270.204% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -30250.163% |
| Biomind Labs Inc. | 1.49 Million USD | -104118.437% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -539.903% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -8386.631% |
| Skye Bioscience, Inc. | 14.07 Million USD | -10998.668% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -77597.96% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1099044.938% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -16399.504% |
| IMV Inc. | 37.93 Million USD | -4017.361% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -776481.674% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -27082.016% |
| GB Sciences, Inc. | 5.41 Million USD | -28729.046% |
| Alpha Cognition Inc. | 7.16 Million USD | -21698.734% |
| HST Global, Inc. | 593.59 Thousand USD | -263014.626% |
| CSL Limited | 18.62 Billion USD | 91.613% |
| Halberd Corporation | 728.71 Thousand USD | -214225.412% |
| Enzolytics Inc. | 365.26 Million USD | -327.583% |
| Resverlogix Corp. | 67.39 Million USD | -2217.393% |
| Affymax, Inc. | 8.87 Million USD | -17506.02% |
| SYBLEU INC | 681.41 Thousand USD | -229104.609% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -186113.236% |
| argenx SE | 444.95 Million USD | -251.012% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -1984.664% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -91021.937% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -13021.203% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -42512.827% |
| AVAX Technologies, Inc. | 3.99 Million USD | -39006.903% |
| Zenith Capital Corp. | 27.56 Thousand USD | -5665067.398% |
| Genscript Biotech Corporation | 1.32 Billion USD | -17.796% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -654332.777% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -41723.836% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -229299.531% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -1215.533% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -17172.688% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2333462.432% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -108824.784% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -3007.254% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -57497.226% |
| BioStem Technologies, Inc. | 15.9 Million USD | -9719.948% |
| ONE Bio Corp. | 27.49 Million USD | -5580.247% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -335994.978% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -5693152.652% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -123934.203% |
| Agentix Corp. | 2.51 Million USD | -62110.547% |
| LadRx Corporation | 2.2 Million USD | -70875.239% |
| Cell Source, Inc. | 15.8 Million USD | -9780.801% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -3494239.538% |
| Regen BioPharma, Inc. | 5.45 Million USD | -28517.44% |
| Regen BioPharma, Inc. | 5.45 Million USD | -28517.44% |
| NovAccess Global Inc. | 7.86 Million USD | -19768.76% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -6211.437% |
| Itoco Inc. | 1.65 Million USD | -94375.943% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -76028.711% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -25719.64% |
| Kadimastem Ltd | 3.5 Million USD | -44461.748% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -370381.156% |
| CytoDyn Inc. | 127.89 Million USD | -1121.191% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -3736424.797% |
| Mobile Lads Corp. | 1.31 Million USD | -118806.248% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -99609.712% |
| Qrons Inc. | 1.48 Million USD | -104811.423% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -14040.237% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -193006.032% |
| Rebus Holdings, Inc. | 5.24 Million USD | -29694.544% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -25495.777% |
| International Stem Cell Corporation | 5.27 Million USD | -29496.93% |
| Bioxytran, Inc. | 3.24 Million USD | -47963.702% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -249469.757% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -33726.894% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -3709.713% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -6914.732% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -77012.67% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -28410.953% |
| Neutra Corp. | 973.52 Thousand USD | -160329.736% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -5282.836% |
| PureTech Health plc | 125.58 Million USD | -1143.664% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -41469.817% |
| IXICO plc | 1.9 Million USD | -82088.948% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -7507.921% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1411.585% |
| CSL Limited | 18.62 Billion USD | 91.613% |
| Cellectis S.A. | 249.36 Million USD | -526.312% |